Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
종목 코드 CADL
회사 이름Candel Therapeutics Inc
상장일Jul 27, 2021
CEOTak (Paul Peter)
직원 수38
유형Ordinary Share
회계 연도 종료Jul 27
주소117 Kendrick Street,
도시NEEDHAM
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02494
전화16179165445
웹사이트https://www.candeltx.com/
종목 코드 CADL
상장일Jul 27, 2021
CEOTak (Paul Peter)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음